Ladybon

Tibolone, the active ingredient in Ladybon, is a synthetic steroid (estrogenic, progestogenic, androgenic) presented as an oral tablet for oral use. It treats menopausal symptoms and estrogen deficiency in post‑menopausal women.

GNH USA supplies Ladybon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tibolone is used in hormone replacement therapy to address estrogen deficiency.

- Relief of menopausal symptoms: reduces hot flashes, night sweats, and mood swings. - Prevention of post‑menopausal osteoporosis: improves bone mineral density. - Treatment of estrogen deficiency: restores hormonal balance in post‑menopausal women. - Management of vulvovaginal atrophy: alleviates dryness and discomfort.

Tibolone may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Breast tenderness: mild swelling or pain. - Weight gain: modest increase in body weight.

Serious or Rare Side Effects: - Venous thromboembolism: risk of blood clots. - Liver dysfunction: abnormal liver enzyme levels. - Severe hypertension: significant increase in blood pressure.

Before initiating tibolone therapy, several safety considerations are recommended.

- Assess cardiovascular risk: evaluate history of thromboembolic disease. - Monitor liver function: perform baseline and periodic tests. - Screen for estrogen‑dependent tumors: avoid in known breast or endometrial cancer. - Consider bone health: use with calcium/vitamin D as needed. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Tibolone can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Combined oral contraceptives: increased risk of thromboembolism. - Anticoagulants (warfarin): may potentiate bleeding risk. - Antihypertensives: may reduce efficacy.

Moderate Interactions (Monitor Closely): - Cytochrome P450 inducers (e.g., rifampin): may lower tibolone levels. - Antidepressants (SSRIs): may affect hot‑flash relief.